id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S6318 R26054 |
Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 | Spina bifida | throughout pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
0.97 [0.02;48.83] C excluded (control group) |
0/613 0/593 | 0 | 613 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6320 R26059 |
Veiby (Carbamazepine) (Controls unexposed, sick), 2014 | Spina bifida | throughout pregnancy | population based cohort retrospective | unexposed, sick | Adjustment: No | 0.88 [0.05;17.04] C | 0/613 3/3,773 | 3 | 613 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S8137 R24993 |
Charlton (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2011 | Spina bifida | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
0.31 [0.01;15.93] C excluded (control group) |
0/311 0/98 | 0 | 311 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S331 R24990 |
Charlton (Carbamazepine) (Controls unexposed, sick), 2011 | Spina bifida | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: No | 0.58 [0.03;12.10] C | 0/311 2/902 | 2 | 311 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S5529 R16225 |
Viinikainen (Carbamazepine) (Controls unexposed, sick) a, 2006 | Spina bifida | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.72 [0.01;36.90] C | 0/72 0/52 | 0 | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S302 R15848 |
Artama (Carbamazepine), 2005 | Spina bifida | 1st trimester | retrospective cohort (registry) | unexposed, sick | Adjustment: No | 1.17 [0.02;58.86] C | 0/805 0/939 | 0 | 805 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6823 R19294 |
Van der Pol (Carbamazepine) (Controls unexposed, disease free), 1991 | Spina bifida occulta | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
5.19 [0.10;276.47] C excluded (control group) |
0/11 0/55 | 0 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6825 R19344 |
Van der Pol (Carbamazepine) (Controls unexposed, sick), 1991 | Spina bifida occulta | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 0.65 [0.02;17.40] C | 0/11 1/22 | 1 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 5 studies | 0.76 [0.17;3.39] | 6 | 1,812 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Carbamazepine) (Controls unexposed, sick; 2: Carbamazepine) (Controls unexposed, sick; 3: Carbamazepine) (Controls unexposed, sick) ; 4: Carbamazepine; 5: Carbamazepine) (Controls unexposed, sick;
Asymetry test p-value = 0.4842 (by Egger's regression)
slope=-1.1015 (1.0387); intercept=0.4830 (0.6068); t=0.7959; p=0.4842
excluded 6823, 8137, 6318